Baxter International | BAX - Interest Expense On Debt


Baxter International reported $58M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Abbott USD 68M 26M Mar/2026
AngioDynamics USD 102K 2K Sep/2025
Artivion USD 5.53M 589K Dec/2025
AtriCure USD 1.37M 42K Dec/2025
Avanos Medical USD 1.9M 100K Dec/2025
Baxter International USD 58M 14M Sep/2025
Becton, Dickinson and Co. USD 149M 4M Mar/2026
Boston Scientific USD 90M 0 Mar/2026
Cooper Companies USD 22.4M 2M Dec/2025
Dexcom USD 4.2M 500K Dec/2025
Edwards Lifesciences USD 35.9M 2.7M Dec/2025
Fresenius EUR 81M 5M Sep/2025
Globus Medical USD 5.44B 5.44B Mar/2026
Halozyme Therapeutics USD 5.51M 597K Mar/2026
ICU Medical USD 20.64M 21.39M Dec/2025
Inogen 1.03M 384K Mar/2025
Insulet USD 14.7M 5.5M Mar/2026
Integra LifeSciences USD 22.46M 1.21M Mar/2026
Intuitive Surgical USD 20.11B 58.39B Mar/2026
J&J USD 43M 25M Mar/2026
Laboratory Of America USD 55.1M 100K Mar/2026
Masimo USD 6.1M 1.4M Mar/2026
Medtronic USD 176M 5M Mar/2026
Merit Medical Systems USD 6.53M 162K Mar/2026
Quest Diagnostics USD 69M 2M Sep/2025
Smith & Nephew USD 69M 1000K Dec/2025
Stryker USD 46.29B 45.68B Mar/2026
Tandem Diabetes Care USD 1.15B 1.15B Mar/2026
Teleflex USD 25.72M 2.43M Mar/2026
Terumo JPY 1.53B 1.06B Mar/2026
Zimmer Biomet Holdings USD 68.8M 3.1M Mar/2026